Profiling the Targets of Protective CD8 + T Cell Responses to Infection
T cells are critical effectors of host immunity that target intracellular pathogens, such as the causative agents of HIV, tuberculosis, and malaria. The development of vaccines that induce effective cell-mediated immunity against such pathogens has proved challenging; for tuberculosis and malaria, m...
Saved in:
Published in | Molecular therapy. Methods & clinical development Vol. 7; no. C; pp. 20 - 31 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Limited
15.12.2017
American Society of Gene & Cell Therapy Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | T cells are critical effectors of host immunity that target intracellular pathogens, such as the causative agents of HIV, tuberculosis, and malaria. The development of vaccines that induce effective cell-mediated immunity against such pathogens has proved challenging; for tuberculosis and malaria, many of the antigens targeted by protective T cells are not known. Here, we report a novel approach for screening large numbers of antigens as potential targets of T cells. Malaria provides an excellent model to test this antigen discovery platform because T cells are critical mediators of protection following immunization with live sporozoite vaccines and the specific antigen targets are unknown. We generated an adenovirus array by cloning 312 highly expressed pre-erythrocytic
antigens into adenovirus vectors using high-throughput methodologies. The array was screened to identify antigen-specific CD8
T cells induced by a live sporozoite vaccine regimen known to provide high levels of sterile protection mediated by CD8
T cells. We identified 69 antigens that were targeted by CD8
T cells induced by this vaccine regimen. The antigen that recalled the highest frequency of CD8
T cells, PY02605, induced protective responses in mice, demonstrating proof of principle for this approach in identifying antigens for vaccine development. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Present Address: PATH’s Malaria Vaccine Initiative, 455 Massachusetts Avenue NW, Suite 1000, Washington, DC 20001, USA Present Address: Summit Consulting, 567 Chestertown Street, Gaithersburg, MD 20878, USA |
ISSN: | 2329-0501 2329-0501 |
DOI: | 10.1016/j.omtm.2017.08.003 |